MLEC

News

accessnewswire.comMoolec Science Successfully Completes 2026 GLASO Commercial Planting Campaign in the United Statesaccessnewswire.comMay 14

accessnewswire.comMoolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Periodaccessnewswire.comMay 13

accessnewswire.comMoolec Science Confirms Completion of First Phase of GLASO Industrialization Following Record 2025 Campaign; Advances 2026 Sowing and Expands Into Energy Applicationsaccessnewswire.comApr 29

accessnewswire.comMoolec Science Announces Breakthrough in Molecular Farming With Successful Expression of Bovine Myoglobin in Pea Seedsaccessnewswire.comApr 7

defenseworld.netMoolec Science (MLEC) Projected to Post Earnings on Tuesdaydefenseworld.netApr 7

Trade MLEC

About Moolec Science S.A.

Moolec Science S.A. is an innovative biotechnology firm specializing in the development of plant-grown animal proteins. Leveraging a transformative method called Molecular Farming, the company is poised to disrupt the alternative protein market. Their product lines and research and development efforts capitalize on the inherent agricultural benefits of select host crops, such as soybeans and peas. Globally, Moolec maintains operations across the United States, Europe, and South America. Established in 2008, the company is headquartered in Luxembourg.

CEO: Alejandro Antalich
IPO Date: Mar 2, 2021

Market Data

Open: $7.78
High: $8.69
Low: $7.24
Volume: 31.8K
Avg Volume: 256K
52W High: $120.00
52W Low: $3.08

Valuation

Market Cap: $5.9M
Enterprise Value: $252M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-30M
Revenue: $334M
Net Income: $-111M
Cash: $768k
Debt: $247M

Events

EarningsMay 14

EPS est. -10.5